The role of vitamin D in melanogenesis with an emphasis on vitiligo

Indian Journal of Dermatology, Venereology and Leprology

Volumn 79, Issue 6, 2013, Pages 750-758

  AlGhamdi, Khalid ^a,b   Kumar, Ashok ^b   Moussa, Noura ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Autoimmune diseases; depigmentation; melanocytes; phototherapy; vitamin D; vitamin D receptor; vitiligo

Indexed keywords

ALPHA INTERFERON; CALCIPOTRIOL; CALCITRIOL; CALCITRIOL RECEPTOR; COLECALCIFEROL; ERGOCALCIFEROL; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LEVODOPA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PSORALEN; TACALCITOL; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR;

BODY SURFACE; BONE METABOLISM; BREAST CANCER; CALCIUM TRANSPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; DIABETES MELLITUS; DIETARY INTAKE; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ELECTRON MICROSCOPY; EMBASE; FAMILY HISTORY; GENE FREQUENCY; GRAFT REJECTION; HAPLOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALABSORPTION; MEDLINE; MELANOCYTE; MELANOGENESIS; MELANOMA B16; MELANOSOME; MULTIPLE SCLEROSIS; NEGATIVE FEEDBACK; NONHUMAN; OBESITY; OSTEOPOROSIS; PATIENT SELECTION; PHOTOTHERAPY; PILOT STUDY; PREMATURITY; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEASONAL VARIATION; SECONDARY HYPERPARATHYROIDISM; SKIN PIGMENTATION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TARGET ORGAN; TREATMENT FAILURE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D RESPONSIVE ELEMENT; VITILIGO; XENON CHLORIDE LASER;

ANIMALS; HUMANS; MELANOCYTES; SKIN PIGMENTATION; VITAMIN D; VITAMIN D DEFICIENCY; VITILIGO;

EID: 84887506688     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.120720     Document Type: Review

References (74)

1. AlGhamdi KM. A survey of vitiligo management among dermatologists in Saudi Arabia. J Eur Acad Dermatol Venereol 2009;23:1282-8.
2. AlGhamdi K, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol 2011;25:749-57.
3. Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: Current treatment options and future directions. Drugs 2004;64:89-107.
4. Mosher DB. Hypomelanoses and Hypermelanoses. In: Freedberg IM, Eisen AZ, Wol VK, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatricks Dermatology in General Medicine. New York: McGraw-Hill; 1999. p. 945-1018.
5. Nordlund JJ. The epidemiology and genetics of vitiligo. Clin Dermatol 1997;15:875-78.
6. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38:647-66.
7. Sigmon JR, Yentzer BA, Feldman SR. Calcitriol ointment: A review of a topical vitamin D analog for psoriasis. J Dermatol Treat 2009;20:208-12.
8. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4-8.
9. Loomis WF. Skin-Pigment regulation of vitamin-D biosynthesis in man. Science 1967;157:501-6.
10. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: Modulator of the immune system. Curr Opin Pharmacol 2010;10:482-96.
11. Van Etten E, Mathieu C. Immunoregulation by 1,25-Dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol 2005;97:93-101.
12. Mora JR, Iwata M, von Adrian UH. Vitamin effects on the immune system: Vitamins A and D take center stage. Nat Rev Immunol 2008;8:685-98.
13. Yasuda H, Higashio K, Suda T. Vitamin D and Osteoclastogenesis. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. vol San Diego, CA: Elsevier Academic Press; 2005. p. 665-85.
14. Wang TT, Tavera-Mendonza LE, Laperriere, D, Libby E, MacLeod NB, Nagai Y, et al. Large-Scale in silico and microarray-Based identification of direct 1,25-Dihydroxivitamin D3 target genes. Mol Endocrinol 2005;19:2685-95.
15. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: New aetiological and therapeutic considerations. Ann Rheum Dis 2007;66:1137-42.
16. Prentice A, Goldberg GR, Schoenmakers I. Vitamin D across the lifecycle: Physiology and biomarkers. Am J Clin Nutr 2008;88:500S-6S.
17. Samuel S, Sitrin MD. Vitamin Ds role in cell proliferation and differentiation. Nutr Rev 2008;66:S116-24.
18. Birlea S, Birlea M, Cimponeriu D, Apostol P, Cosqarea R, Gavrila L, et al. Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Derm Venereol 2006;86:209-14.
19. Li K, Shi Q, Yang L, Li X, Liu L, Wang L, et al. The association of vitamin D receptor gene polymorphisms and serum 25-Hydroxyvitamin D levels with generalized vitiligo. Br J Dermatol 2012;167:815-21.
20. Aydngöz IE, Bingül I, Doru-Abbasolu S, Vural P, Uysal M. Analysis of vitamin D receptor gene polymorphisms in vitiligo. Dermatology 2012;224:361-8.
21. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocrine Rev 2001;22:477-501.
22. Marzano AV, Trevisan V, Eller-Vainicher C, Cairoli E, Marchese L, Morelli V, et al. Evidence for vitamin D deficiency and increased prevalence of fractures in autoimmune bullous skin diseases. Br J Dermatol 2012;167:688-91.
23. Nunes JP, Martins CS. Myocardial infarction, hypovitaminosis D and vitiligo. Rev Port Cardiol 2010;29:839-40.
24. Holick MF. McCollum award lecture 1994: Vitamin D: New horizons for the 21st century. Am J Clin Nutr 1994;60:619-30.
25. Grootjans-Geerts I. Hypovitaminosis D: A veiled diagnosis. Ned Tijdschr Geneeskd 2001;145:2057-60.
26. Gannage-Yared MH, Chemali R, Yaacoub N, Halaby G. Hypovitaminosis D in a sunny country: Relation to lifestyle and bone markers. J Bone Miner Res 2000;15:1856-62.
27. Willis CM, Laing EM, Hall DB, Hausman DB, Lewis RD. A prospective analysis of plasma 25-Hydroxyvitamin D concentrations in white and black prepubertal females in the southeastern United States. Am J Clin Nutr 2007;85:124-30.
28. Neuhouser ML, Sorensen B, Hollis BW, Ambs A, Ulrich CM, McTiernan A, et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 2008;88:133-9.
29. Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, Ursin G, et al. Vitamin D receptor polymorphisms and breast cancer risk in a large population-Based case-Control study of Caucasian and African-American women. Breast Cancer Res 2007;9:R84.
30. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008;4:404-12.
31. Kamen DL, Aranow C. The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep 2008;10:273-80.
32. Liu E, Meigs JB, Pittas AG, McKeown NM, Economos CD, Booth SL, et al. Plasma 25-Hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009;139:329-34.
33. Tremlett H, Van Der Mei IA, Pittas F, Blizzard L, Paley G, Mesaros D, et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008;31:271-9.
34. Oikawa A, Nakayasu M. Stimulation of melanogenesis in cultured melanoma cells by calciferols. FEBS Lett 1974;42:32-5.
35. Tomita Y, Torinuki W, Tagami H. Stimulation of human melanocytes by vitamin D3 possibly mediates skin pigmentation after sun exposure. J Invest Dermatol 1988;90:882-4.
36. Watabe H, Soma Y, Kawa Y, Ito M, Ooka S, Ohsumi K, et al. Differentiation of murine melanocyte precursors induced by 1,25-Dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol 2002;119:583-9.
37. Xu QX, Du J, He PY, Zhang JZ, Zhu TJ. Effects of 1alpha, 25-Dihydroxyvitamin D(3) and UVB on cell proliferation and melanin synthesis of cultured human melanocyte. Beijing Da Xue Xue Bao 2004;36:483-6.
38. Birlea SA, Costin GE, Norri DA. New insights on therapy with Vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Med Res Rev 2009;29:514-46.
39. Mansur CP, Gordon PR, Ray S, Holick MF, Gilchrest BA. Vitamin D, its precursors, and metabolites do not affect melanization of cultured human melanocytes. J Invest Dermatol 1988;91:16-21
40. Hong DK, Kim TJY, Park JK, Haw CR. Effect of calcipotriol (MC 903), a novel synthetic derivative of vitamin D on the growth of cultured human keratinocytes and melanocytes. Korean J Dermatol 1992;30:811-23.
41. Abdel-Malek ZA, Ross R, Trinkle L, Swope V, Pike JW, Nordlund JJ. Hormonal effects of vitamin D3 on epidermal melanocytes. J Cell Physiol 1988;136:273-80.
42. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998;197:167-70.
43. Parsad D, Kanwar AJ. Topical vitamin D3 analogues in the treatment of vitiligo. Pigment Cell Melanoma Res 2009;22:487-8.
44. Oh SH, Kim T, Jee H, Do JE, Lee JH. Combination treatment of nonsegmental vitiligo with a 308-Nm xenon chloride excimer laser and topical high-Concentration tacalcitol: A prospective, single-Blinded, paired, comparative study. J Am Acad Dermatol 2011;65:428-30.
45. Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol 2010;62:937-41.
46. Hartmann A, Lurz C, Hamm H, Brocker EB, Hofmann UB. Narrow-Band UVB 311-Nm vs. broad-Band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005;44:736-42.
47. Baysal V, Yildirim M, Erel A, Kesici D. Is the combination of calcipotriol and PUVA effective in vitiligo J Eur Acad Dermatol Venereol 2003;17:299-302.
48. Yalçn B, Sahin S, Bükülmez G, Karaduman A, Atakan N, Akan T, et al. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: A preliminary study. J Am Acad Dermatol 2001;44:634-7.
49. Tadokoro T, Yamaguchi Y, Batzer J, Coelho SG, Zmudzka BZ, Miller SA, et al. Mechanisms of skin tanning in different racial/ ethnic groups in response to ultraviolet radiation. J Invest Dermatol 2005;124:1326-32.
50. Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol A placebo-Controlled double-Blind study. Br J Dermatol 2001;145:472-5.
51. Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol 2004;50:63-7.
52. Cicarma E, Mørk C, Porojnicu AC, Juzeniene A, Tam TT, Dahlback A, et al. Influence of narrowband UVB phototherapy on vitamin D and folate status. Exp Dermatol 2010;19:e67-72.
53. Schallreuter-Wood KU, Pittelkow MR, Swanson NN. Defective calcium transport in vitiliginous melanocytes. Arch Dermatol Res 1996;288:11-3.
54. Nordlund JJ, Abdel-Malek ZA, Boissy RE, Rheins LA. Pigment cell biology: An historical review. J Invest Dermatol 1989; 92:53-9.
55. Dahl MV. Imiquimod: A cytokine inducer. J Am Acad Dermatol 2002;47:S205-8.
56. Koizumi H, Kaplan A, Shimizu T, Ohkawara A. 1,25-Dihydroxyvitamin D3 and a new analogue, 22-Oxacalcitriol, modulate proliferation and interleukin-8 secretion of normal human keratinocytes. J Dermatol Sci 1997;15:207-13.
57. Penna G, Adorini L. 1 Alpha, 25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405-11.
58. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-Dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:6800-5.
59. Lemire JM, Archer DC. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-7.
60. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994;37:552-8.
61. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128:68-72.
62. Cantorna M, Munsick TC, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000;130:2648-52.
63. Van Etten E, Branisteanu DD, Overbergh L, Bouillon R, Verstuyf A, Mathieu C. Combination of a 1,25-Dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 2003;32:397-404.
64. Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 2008;9:345-59.
65. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167-81.
66. Huang CL, Nordlund JJ, Boissy R. Vitiligo: A manifestation of apoptosis Am J Clin Dermatol 2002;3:301-8.
67. De Haes P, Garmyn M, Degreef H, Vantieghem K, Bouillon R, Seqaert S. 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-Induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. J Cell Biochem 2003;89:663-73.
68. Mason RS, Holliday CJ. 1,25-Dihydroxyvitamin D Contributes to Photoprotection in Skin Cells. In: Norman A, Bouillon R, Thomasset M, editors. Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects. Riverside: University of California; 2000. p. 605-8.
69. Sauer B, Ruwisch L, Kleuser B. Antiapoptotic action of 1alpha, 25-Dihydroxyvitamin D3 in primary human melanocytes. Melanoma Res 2003;13:339-4770.
70. Broyna AA, Jozwicki W, Janjetovic Z, Slominski AT. Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 2011;42:618-31.
71. AlGhamdi KM, Kumar A, Taieb A, Ezzedine K. Assessment Methods for the Evaluation of Vitiligo. J Eur Acad Dermatol Venereol 2012;26:1463-71.
72. Wong G, Gupta R, Dixon KM, Deo SS, Choong SM, Halliday GM, et al. 1,25-Dihydroxyvitamin D and three low-Calcemic analogs decrease UV-Induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Biol 2004; 89-90:567-70.
73. Lu-Yan T, Wen-Wen F, Lei-Hong X, Yi J, Zhi-Zhong Z. Topical tacalcitol and 308-Nm monochromatic excimer light: A synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2006;22:310-4.
74. Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis 2007;28:390-7.